WINT Windtree Therapeutics
- 4.4900
- +0.1900+4.42%
Windtree Therapeutics News
10-Q: Quarterly report
Windtree Therapeutics Regains Compliance With Nasdaq
Windtree Therapeutics, Inc. ("Windtree" or the "Company") (NasdaqCM: WINT), a biotechnology company focused on advancing early and late-stage innovative therapies for critical conditions and diseases,
Immutep, Capricor Therapeutics, Cyclacel Pharmaceuticals Among Healthcare Movers
Lexicon Pharmaceuticals, Bio-Path Holdings, Protara Therapeutics Among Healthcare Movers
Windtree Therapeutics To Carry Out 1-for-18 Reverse Stock Split On April 22nd, 2024
April 19th - $Windtree Therapeutics(WINT.US)$ is about to implement a 1-for-18 reverse stock split of shares. The shares will begin trading on a split-adjusted basis from April 22nd, 2024.$Windtree Th
Why Windtree Therapeutics (WINT) Stock Is Getting Hammered
Windtree Therapeutics Inc (NASDAQ:WINT) shares are trading lower by 20% to $0.32 during Thursday's session after the company announced it approved a 1-for-18 reverse stock split of its common stock. T
Windtree Therapeutics Shares Are Trading Lower After the Company Approved a 1-for-18 Reverse Stock Split.
Windtree Therapeutics Shares Are Trading Lower After the Company Approved a 1-for-18 Reverse Stock Split.
Why Las Vegas Sands Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Shares of Las Vegas Sands Corp. (NYSE:LVS) fell sharply during Thursday's session despite better-than-expected first-quarter results.The company reported quarterly adjusted earnings of 75 cents per sh
Windtree Therapeutics: Split Will Increase Market Price Per Shr of Company's Common Stk, Bringing Co Into Compliance With Listing Requirements of $1 Minimum Bid Price Requirement by Nasdaq Cap Market >WINT
Windtree Therapeutics: Split Will Increase Market Price Per Shr of Company's Common Stk, Bringing Co Into Compliance With Listing Requirements of $1 Minimum Bid Price Requirement by Nasdaq Cap Market
Windtree Therapeutics Announces 1-For-18 Reverse Stk Split >WINT
Windtree Therapeutics Announces 1-For-18 Reverse Stk Split >WINT
Windtree Therapeutics Q4 2023 GAAP EPS $(0.95) Misses $(0.94) Estimate
Windtree Therapeutics (NASDAQ:WINT) reported quarterly losses of $(0.95) per share which missed the analyst consensus estimate of $(0.94) by 1.06 percent.
Windtree Therapeutics: Cash and Cash Equivalents $4.3M as at Dec. 31 >WINT
Windtree Therapeutics: Cash and Cash Equivalents $4.3M as at Dec. 31 >WINT
Windtree Therapeutics 4Q Loss/Shr 95c >WINT
Windtree Therapeutics 4Q Loss/Shr 95c >WINT
Windtree Therapeutics (WINT.US): The 2023 Q4 earnings report achieved revenue of $0, previous value of $0; earnings per share were -$0.74, previous value was -$13.01, and expected value was -$0.94.
Windtree Therapeutics (WINT.US): The 2023 Q4 earnings report achieved revenue of $0, previous value of $0; earnings per share were -$0.74, previous value was -$13.01, and expected value was -$0.94.
Windtree Therapeutics Shares Are Trading Lower. The Company Announced That It Entered Into an Asset Purchase Agreement With Varian Biopharmaceuticals to Acquire Certain Assets.
Windtree Therapeutics Shares Are Trading Lower. The Company Announced That It Entered Into an Asset Purchase Agreement With Varian Biopharmaceuticals to Acquire Certain Assets.
Windtree Therapeutics to Acquire Cancer Treatment From Varian Biopharmaceuticals
Windtree Therapeutics (WINT) said Monday it has agreed to acquire a cancer treatment therapy from Varian Biopharmaceuticals. The therapy from Varian, which comes in oral and topical forms, is a protei
Windtree Enter Asset Purchase Agreement With Varian Biopharmaceuticals To Acquire Certain Of Its Assets, Including A Proprietary Atypical Protein Kinase C Iota Inhibitor
The Company also completed a $1.5 million convertible note bridge financing. With successful development, the Company would pay up to $2.3 million in milestone payments upon the achievement of certain
Windtree Acquires Early-Stage, Novel Oncology Platform And Completes $1.5 Million Convertible Note Bridge Financing >WINT
Windtree Acquires Early-Stage, Novel Oncology Platform And Completes $1.5 Million Convertible Note Bridge Financing >WINT
Press Release: Windtree Acquires Early-Stage, Novel Oncology Platform and Completes $1.5 Million Convertible Note Bridge Financing
WARRINGTON, Pa., April 08, 2024 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. ("Windtree" or the "Company") (NasdaqCM: WINT), today announced that on April 2, 2024 the Company entered into an asset purchase agreement with Varian Biopharmaceuticals, Inc. ("Varian") to acquire certain of its assets, including a proprietary atypical protein kinase C iota inhibitor (aPKCi).
Windtree Therapeutics CFO Resigns Amid Cost-Cutting Measures
Analysis
Price Target
No Data
